{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T13:04:17Z","timestamp":1780923857708,"version":"3.54.1"},"reference-count":19,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100020604","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020604","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Despite improvements in post-acute myocardial infarction (AMI) care, the risk of subsequent cardiovascular (CV) events remains substantial, particularly heart failure (HF) in patients with left ventricular systolic dysfunction (LVSD) and\/or pulmonary congestion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The PARADISE-MI trial randomized 5661 patients with AMI complicated by LVSD and\/or pulmonary congestion to sacubitril\/valsartan (97\/103\u2005mg b.i.d.) or ramipril (5\u2005mg b.i.d.) at a mean of 4 days post-AMI. This post hoc analysis described the timing and distribution of CV events and compared treatment effects in early (\u22643 months) and late (&amp;gt;3 months) post-AMI periods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Post-AMI, CV events peaked early; HF was the most frequent [16.2\/100 patient-years (py)], followed by CV death (11.6\/100 py) and recurrent MI (10.9\/100 py). Later, HF remained predominant (3.2\/100 py vs 2.6\/100 py for MI, P = .008; CV death 2.1\/100 py). Early post-AMI, patients with HF or recurrent MI shared similar profiles. Later, HF patients were predominantly older and female, with greater pulmonary congestion and lower eGFR; recurrent MI patients had more frequent history of coronary revascularization. Only sacubitril\/valsartan showed a favourable influence late post-AMI (HR 0.76, 95% CI 0.60\u20131.00, P = .05) and expanded CV composite outcome (CV death, HF events, recurrent MI, hospitalization for angina, or post-randomization coronary revascularization) benefit over the trial (HR = 0.87, 95% CI 0.77\u20130.97, P = .012).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Post-AMI, HF predominates both early and late among CV events. Compared with ramipril, sacubitril\/valsartan was associated with a possible late reduction in recurrent MI and a modest decrease in an expanded CV composite outcome that merits further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejhf\/xuag176","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:46:01Z","timestamp":1779363961000},"source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular events after acute myocardial infarction complicated by low ejection fraction and\/or congestion: a landmark analysis of the PARADISE-MI trial"],"prefix":"10.1093","author":[{"given":"Jacinthe","family":"Boulet","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Cardiology, Montreal Heart Institute, Universit\u00e9 de Montr\u00e9al , 5000 Belanger Street, Montr\u00e9al, QC H1T1C8 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Lucien","family":"Rouleau","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, Montreal Heart Institute, Universit\u00e9 de Montr\u00e9al , 5000 Belanger Street, Montr\u00e9al, QC H1T1C8 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Petrie","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Claggett","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, and Harvard Medical School, Boston , MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldrin F","family":"Lewis","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford University , Palo Alto, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A","family":"Pfeffer","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, and Harvard Medical School, Boston , MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Kulac","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, and Harvard Medical School, Boston , MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Morais","sequence":"additional","affiliation":[{"name":"ciTechCare\u2014Center for Innovative Care and Health Technology, Polytechnic Institute of Leiria , Leiria ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9989-0730","authenticated-orcid":false,"given":"Ivo","family":"Petrov","sequence":"additional","affiliation":[{"name":"Head of Cardiology, Angiology and Electrophysiology Department, Acibadem City Clinic , Sofia ,","place":["Bulgaria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5502-7882","authenticated-orcid":false,"given":"Michele","family":"Senni","sequence":"additional","affiliation":[{"name":"Cardiology Division, Cardiovascular Department, Hospital Papa Giovanni XXIII , Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Francois","family":"Tanguay","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, Montreal Heart Institute, Universit\u00e9 de Montr\u00e9al , 5000 Belanger Street, Montr\u00e9al, QC H1T1C8 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5686-7752","authenticated-orcid":false,"given":"Petr","family":"Widimsk\u00fd","sequence":"additional","affiliation":[{"name":"Cardiocenter, Charles University , Prague ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3472-626X","authenticated-orcid":false,"given":"Eugene","family":"Braunwald","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Brigham and Women\u2019s Hospital, and Harvard Medical School, Boston , MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"2026060808264218700_xuag176-B1","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1161\/CIRCULATIONAHA.120.047065","article-title":"Trends in recurrent coronary heart disease after myocardial infarction among US women and men between 2008 and 2017","volume":"143","author":"Peters","year":"2021","journal-title":"Circulation"},{"key":"2026060808264218700_xuag176-B2","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","article-title":"Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective","volume":"36","author":"Jernberg","year":"2015","journal-title":"Eur Heart J"},{"key":"2026060808264218700_xuag176-B3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1093\/eurjhf\/hfq194","article-title":"Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction","volume":"13","author":"Thune","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"2026060808264218700_xuag176-B4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jchf.2017.09.015","article-title":"Post-myocardial infarction heart failure","volume":"6","author":"Bahit","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026060808264218700_xuag176-B5","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa2104508","article-title":"Angiotensin receptor\u2013neprilysin inhibition in acute myocardial infarction","volume":"385","author":"Pfeffer","year":"2021","journal-title":"N Engl J Med"},{"key":"2026060808264218700_xuag176-B6","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1161\/CIRCULATIONAHA.122.060841","article-title":"The effects of angiotensin receptor-neprilysin inhibition on major coronary events in patients with acute myocardial infarction: insights from the PARADISE-MI trial","volume":"146","author":"Mehran","year":"2022","journal-title":"Circulation"},{"key":"2026060808264218700_xuag176-B7","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/ejhf.2191","article-title":"Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics","volume":"23","author":"Jering","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026060808264218700_xuag176-B8","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"2026060808264218700_xuag176-B9","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"2026060808264218700_xuag176-B10","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A clinical trial of the angiotensin-converting\u2013enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction","volume":"333","author":"K\u00f8ber","year":"1995","journal-title":"N Engl J Med"},{"key":"2026060808264218700_xuag176-B11","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","article-title":"Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group","volume":"355","author":"Flather","year":"2000","journal-title":"Lancet"},{"key":"2026060808264218700_xuag176-B12","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1093\/eurheartj\/ehn062","article-title":"Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and\/or left ventricular dysfunction: a VALIANT study","volume":"29","author":"Lewis","year":"2008","journal-title":"Eur Heart J"},{"key":"2026060808264218700_xuag176-B13","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1161\/CIRCULATIONAHA.124.069217","article-title":"Effect of empagliflozin on heart failure outcomes after acute myocardial infarction: insights from the EMPACT-MI trial","volume":"149","author":"Hernandez","year":"2024","journal-title":"Circulation"},{"key":"2026060808264218700_xuag176-B14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1161\/CIRCULATIONAHA.121.057429","article-title":"Impact of sacubitril\/valsartan versus ramipril on total heart failure events in the PARADISE-MI trial","volume":"145","author":"Pfeffer","year":"2022","journal-title":"Circulation"},{"key":"2026060808264218700_xuag176-B15","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"322","author":"Desai","year":"2019","journal-title":"JAMA"},{"key":"2026060808264218700_xuag176-B16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1161\/CIRCULATIONAHA.121.054892","article-title":"Effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction","volume":"144","author":"Docherty","year":"2021","journal-title":"Circulation"},{"key":"2026060808264218700_xuag176-B17","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"2026060808264218700_xuag176-B18","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S0140-6736(02)08351-4","article-title":"Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up","volume":"359","author":"LIPID Study Group","year":"2002","journal-title":"Lancet"},{"key":"2026060808264218700_xuag176-B19","doi-asserted-by":"publisher","first-page":"6509","DOI":"10.1038\/s41598-019-42994-1","article-title":"Neprilysin inhibitor-angiotensin II receptor blocker combination therapy (Sacubitril\/valsartan) suppresses atherosclerotic plaque formation and inhibits inflammation in apolipoprotein E- deficient mice","volume":"9","author":"Zhang","year":"2019","journal-title":"Sci Rep"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag176\/68372363\/xuag176.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag176\/68372363\/xuag176.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:26:48Z","timestamp":1780921608000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article\/doi\/10.1093\/ejhf\/xuag176\/8691120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":19,"URL":"https:\/\/doi.org\/10.1093\/ejhf\/xuag176","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"article-number":"xuag176"}}